{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T22:24:48Z","timestamp":1776896688693,"version":"3.51.2"},"reference-count":21,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005888","name":"Medical University of Lodz","doi-asserted-by":"publisher","award":["503\/1-152-01\/503-11-002"],"award-info":[{"award-number":["503\/1-152-01\/503-11-002"]}],"id":[{"id":"10.13039\/501100005888","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objectives: This study is a retrospective analysis of patients with plaque psoriasis treated with biological drugs at a single center in Poland. We sought to evaluate patient demographics, disease characteristics, comorbidity burden, and treatment patterns in this cohort. Methods: Data were collected from the medical records of patients with plaque psoriasis who received biological treatments. In total, data from 1 January 2013 to 2 August 2024 were analyzed, encompassing 159 patients. The variables analyzed included age, disease duration, affected areas, prior treatments, and treatment outcomes. Results: The mean age at the start of biological treatment was 48 years (range: 10\u201373 years), with an average psoriasis duration of 18.2 years (range: 1\u201351 years). Obesity was noted in 39% of patients. Psoriasis lesions commonly affected the scalp (74.66%) and nails (64.38%). Methotrexate was the most commonly used systemic therapy prior to biologics (86.30%). Risankizumab and adalimumab were the most frequently prescribed biologics. Secondary treatment failure led to the highest discontinuation rates with tildrakizumab, whereas bimekizumab, guselkumab, risankizumab, and secukinumab showed the lowest rates. Conclusions: Biological drugs play a pivotal role in managing plaque psoriasis, particularly for patients with comorbidities and in treating challenging areas such as the scalp and nails. Risankizumab and adalimumab were prominent in prescription patterns. Future research involving larger cohorts and prospective designs is needed to deepen understanding and optimize treatment strategies for plaque psoriasis in Poland.<\/jats:p>","DOI":"10.3390\/jcm13247647","type":"journal-article","created":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T03:46:02Z","timestamp":1734407162000},"page":"7647","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Demographics, Disease Characteristics, and Treatment Patterns of Patients with Plaque Psoriasis Treated with Biological Drugs: The Experience of a Single-Centre Study in Poland"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8194-0867","authenticated-orcid":false,"given":"Agnieszka","family":"Kimak-Pielas","sequence":"first","affiliation":[{"name":"Department of Dermatology and Venereology, Teaching Hospital No. 2, 90-549 Lodz, Poland"},{"name":"Department of Dermatology, Medical University of Lodz, 90-647 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4633-9160","authenticated-orcid":false,"given":"Ewa","family":"Robak","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Teaching Hospital No. 2, 90-549 Lodz, Poland"},{"name":"Department of Dermatology, Medical University of Lodz, 90-647 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rados\u0142aw","family":"Zajdel","sequence":"additional","affiliation":[{"name":"Department of Economic and Medical Informatics, University of Lodz, 90-214 Lodz, Poland"},{"name":"Department of Medical Informatics and Statistics, Medical University of Lodz, 90-645 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnieszka","family":"\u017bebrowska","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, Teaching Hospital No. 2, 90-549 Lodz, Poland"},{"name":"Department of Dermatology, Medical University of Lodz, 90-647 Lodz, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/1346-8138.15840","article-title":"Psoriasis: Comorbidities","volume":"48","author":"Yamazaki","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_2","first-page":"693","article-title":"Epidemiology of psoriasis in the years 2008\u20132015 in Poland","volume":"105","author":"Koncewicz","year":"2019","journal-title":"Dermatol. Rev.\/Przegl\u0105d Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Bu, J., Ding, R., Zhou, L., Chen, X., and Shen, E. (2022). Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.880201"},{"key":"ref_4","unstructured":"(2024, December 15). NHS Drug Programs, Available online: https:\/\/www.gov.pl\/web\/zdrowie\/programy-lekowe."},{"key":"ref_5","unstructured":"(2024, December 15). NHS Drug Program Sites, Available online: https:\/\/gsl.nfz.gov.pl\/GSL\/GSL\/ProgramyLekowe."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00403-015-1593-8","article-title":"Drug safety of systemic treatments for psoriasis: Results from The German Psoriasis Registry PsoBest","volume":"307","author":"Reich","year":"2015","journal-title":"Arch. Dermatol. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/bjd.18333","article-title":"Psoriasis treat to target: Defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR)","volume":"182","author":"Mahil","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/JDN.0000000000000418","article-title":"Manifestations and Management of Difficult-to-Treat Psoriasis","volume":"10","author":"Aldredge","year":"2018","journal-title":"J. Dermatol. Nurses Assoc."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Egeberg, A., See, K., Garrelts, A., and Burge, R. (2020). Epidemiology of psoriasis in hard-to-treat body locations: Data from the Danish skin cohort. BMC Dermatol., 20.","DOI":"10.1186\/s12895-020-00099-7"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/bjd.17403","article-title":"Topology of psoriasis in routine care: Results from high-resolution analysis of 2009 patients","volume":"181","author":"Augustin","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/ced.12805","article-title":"Prevalence of psoriasis phenotypes among men and women in the USA","volume":"41","author":"Merola","year":"2016","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2287401","DOI":"10.1080\/09546634.2023.2287401","article-title":"Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: An analysis from the CorEvitas psoriasis registry","volume":"35","author":"Strober","year":"2024","journal-title":"J. Dermatol. Treat."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Giordano, S., Dapavo, P., Ortoncelli, M., Stroppiana, E., Verrone, A., Quaglino, P., Ribero, S., and Mastorino, L. (2023). Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience. J. Clin. Med., 12.","DOI":"10.3390\/jcm12247503"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2199108","DOI":"10.1080\/09546634.2023.2199108","article-title":"Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: A real-life retrospective study","volume":"34","author":"Ibba","year":"2023","journal-title":"J. Dermatol. Treat."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e15166","DOI":"10.1111\/dth.15166","article-title":"Real-world evidence of biologic treatments in moderate\u2013severe psoriasis in Italy: Results of the CANOVA (EffeCtiveness of biologic treAtmeNts for plaque psOriasis in Italy: An obserVAtional longitudinal study of real-life clinical practice) study","volume":"35","author":"Colombo","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_16","unstructured":"(2024, December 01). Methotrexate 25 mg\/mL Injection\u2014Summary of Product Characteristics (SmPC)\u2014(emc). Available online: https:\/\/www.medicines.org.uk\/emc\/product\/1404\/smpc#gref."},{"key":"ref_17","unstructured":"(2024, December 01). Acitretin 10 mg Capsules\u2014Summary of Product Characteristics (SmPC)\u2014(emc). Available online: https:\/\/www.medicines.org.uk\/emc\/product\/5265\/smpc#gref."},{"key":"ref_18","unstructured":"(2024, December 01). Neoral Soft Gelatin Capsules\u2014Summary of Product Characteristics (SmPC)\u2014(emc). Available online: https:\/\/www.medicines.org.uk\/emc\/product\/1034\/smpc#gref."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/jamadermatol.2023.4846","article-title":"Risk of Paradoxical Eczema in Patients Receiving Biologics for Psoriasis","volume":"160","author":"Alabas","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1177\/12034754231188444","article-title":"A Systematic Review and Meta-Analysis of Injection Site Reactions in Randomized-Controlled Trials of Biologic Injections","volume":"27","author":"Kim","year":"2023","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Karampinis, E., Papadopoulou, M.M., Chaidaki, K., Georgopoulou, K.E., Magaliou, S., Roussaki Schulze, A.V., Bogdanos, D.P., and Zafiriou, E. (2024). Plaque Psoriasis Exacerbation and COVID-19 Vaccination: Assessing the Characteristics of the Flare and the Exposome Parameters. Vaccines, 12.","DOI":"10.3390\/vaccines12020178"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/24\/7647\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:52:50Z","timestamp":1760115170000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/24\/7647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":21,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["jcm13247647"],"URL":"https:\/\/doi.org\/10.3390\/jcm13247647","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]}}}